In recent years, oligonucleotides, as a highly promising innovative drug, have been successively approved for marketing by the US FDA and the European EMA, bringing hope to treatment of genetic and rare diseases that lack effective therapeutic means, and representing a new wave of modern new drugs. Neo-leading, as a subsidiary of BociMed providing synthetic services, can provide a variety of nucleoside products, modified nucleosides, phosphoramidite monomers, and molecular building blocks required for the development of new small-nucleic acid drugs, etc. We also provide FTE services, CMC services, and CDMO services for the process development of small molecules and peptide drugs.